Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month Low – Time to Sell?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reached a new 52-week low during mid-day trading on Thursday. The stock traded as low as $179.87 and last traded at $195.2640, with a volume of 671,226 shares. The stock had previously closed at $232.40.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several analyst reports. Cantor Fitzgerald reissued a “neutral” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 30th. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. Barclays lowered their price target on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. Bank of America decreased their price objective on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Finally, UBS Group began coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, October 15th. They issued a “buy” rating and a $354.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $364.95.

Alnylam Pharmaceuticals Price Performance

The stock’s 50 day simple moving average is $239.15 and its 200-day simple moving average is $288.34. The stock has a market capitalization of $25.24 billion, a price-to-earnings ratio of 35.27 and a beta of 0.28. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating the consensus estimate of $1.66 by $14.60. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The business’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the company earned $2.90 earnings per share. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.43 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ALNY. Legal & General Group Plc bought a new position in Alnylam Pharmaceuticals in the second quarter valued at about $278,321,000. Bank of New York Mellon Corp bought a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $148,128,000. Canada Pension Plan Investment Board acquired a new stake in Alnylam Pharmaceuticals in the second quarter worth $100,618,000. Korea Investment CORP acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $74,553,000. Finally, Wellington Management Group LLP increased its position in shares of Alnylam Pharmaceuticals by 9.0% in the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock valued at $635,296,000 after buying an additional 174,482 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.